GPR34 Antibody

What is GPR34 and why is it significant in research settings?

GPR34 is a lysophosphatidylserine (lysoPS)-responsive G-protein coupled receptor predominantly expressed in immune cells, particularly microglia and mast cells . Its significance stems from its pathogenic roles in numerous diseases, including neuropathic pain, autoimmune conditions, and various cancers such as glioma . Recent structural studies using cryo-electron microscopy have advanced our understanding of both activated and inactivated states of GPR34, enhancing its potential as a therapeutic target . The receptor's involvement in immune cell function and pathological processes makes GPR34 antibodies essential tools for studying its expression, localization, and functional mechanisms in diverse research contexts.

What are the primary validated cell models for GPR34 antibody applications?

Several cell models have been validated for GPR34 antibody applications across different experimental techniques:

These validated models provide researchers with established systems for investigating GPR34 expression and function with proven antibody efficacy .

How can I distinguish between phosphorylated and non-phosphorylated GPR34 in my experiments?

To distinguish between phosphorylated and non-phosphorylated forms of GPR34, researchers should employ antibodies specifically designed for this purpose. The non-phospho-GPR34 receptor antibody (such as 7TM0101N) is directed against the distal end of the carboxyl-terminal tail of human GPR34 and can detect total GPR34 receptors in Western blots independent of phosphorylation status . For specific phosphorylation sites, phospho-specific antibodies would be required.

When designing experiments to differentiate these forms:

• Use phosphorylation-independent antibodies (like 7TM0101N) to detect total GPR34 levels

• Compare results with phospho-specific antibodies (if available) in parallel samples

• Incorporate phosphatase treatments as controls to confirm specificity

• Validate results using appropriate transfected cell models expressing wild-type or mutant GPR34

This approach is particularly relevant when studying GPR34 signaling mechanisms, as phosphorylation states can significantly affect receptor function and trafficking.

How do gain-of-function mutations in GPR34 affect antibody binding and experimental design?

Gain-of-function (GOF) mutations in GPR34, particularly C-terminal truncations such as R337X and Q340X, can significantly impact antibody binding and experimental design . These truncations, commonly found in mucosa-associated lymphoid tissue (MALT) lymphoma, alter receptor signaling and potentially epitope accessibility .

When designing experiments involving GPR34 GOF mutations:

• Antibody selection: Choose antibodies targeting epitopes unaffected by the truncation. For C-terminal truncations, N-terminal or transmembrane domain-targeted antibodies may be more reliable

• Positive controls: Include both wild-type and mutant GPR34 expressions systems for comparison

• Functional validation: Complement binding studies with functional assays, as truncated GPR34 (R337X) demonstrates enhanced migration to lysoPS compared to wild-type receptor

• Reporter systems: Consider using GFP-reporter constructs alongside antibody detection to track expression of mutant receptors

Researchers should be aware that truncated GPR34 may exhibit altered subcellular localization, internalization rates, and signaling properties, necessitating careful experimental design and interpretation .

What are the optimal methodological approaches for studying GPR34's role in immune cell infiltration?

Research indicates that GPR34 expression positively correlates with immune cell infiltration in several pathological contexts, particularly in glioma . When investigating this relationship, researchers should consider these methodological approaches:

• Correlation analysis: Use Spearman correlation coefficients to assess associations between GPR34 expression and immune cell populations. Research has shown strong positive correlations between GPR34 and macrophages (r=0.588), neutrophils (r=0.535), and immature dendritic cells (r=0.460)

• Single-sample Gene Set Enrichment Analysis (ssGSEA): This approach effectively quantifies immune infiltration levels associated with GPR34 expression patterns

• Flow cytometry validation: Following computational analyses, validate findings using flow cytometry with markers for specific immune cell populations alongside GPR34 antibodies

• Tissue-specific considerations: Different tissues may show distinct patterns of GPR34-associated immune infiltration. For example, the peritoneal cavity demonstrates particular sensitivity to GPR34 expression levels in plasma cells and memory B cells

• Transgenic models: Utilize GPR34 knock-in or knockout models to assess causative relationships between GPR34 expression and immune cell infiltration

This multi-modal approach provides robust assessment of GPR34's influence on immune cell recruitment and function across different pathological contexts.

How can GPR34 antibodies be employed in studying its role in glioma progression?

GPR34 has been identified as a potential oncogene in glioma, with higher expression associated with poorer prognosis . When investigating GPR34's role in glioma progression, researchers should consider these antibody-dependent approaches:

• Expression profiling: Use immunohistochemistry with validated GPR34 antibodies to correlate expression levels with clinical outcomes and pathological features across glioma grades

• Functional studies: Employ GPR34 antibodies in combination with knockdown or overexpression systems in glioma cell lines (U251, LN229) to assess:

  • Viability (using Cell Counting Kit-8 assays)

  • Colony formation capacity

  • Migration (wound healing assays)

  • Invasion (Transwell assays)

• Pathway analysis: Combine GPR34 antibody detection with markers of:

  • Epithelial-mesenchymal transition (EMT)

  • Cell cycle regulation (G1/S phase transition)

  • TGF-β/Smad signaling activation

• Therapeutic potential: Test GPR34 antagonists alongside antibody-based detection to validate target engagement and monitor pathway modulation

These approaches enable comprehensive investigation of GPR34's mechanistic contributions to glioma pathogenesis, potentially revealing therapeutic opportunities.

What are the optimal conditions for immunofluorescence detection of GPR34 in different cell types?

For optimal immunofluorescence detection of GPR34, conditions should be tailored to specific cell types:

In A172 human glioblastoma cells:

• Mouse Anti-Human GPR34 Monoclonal Antibody (MAB4617) at 10 μg/mL

• Incubation time: 3 hours at room temperature

• Fixation method: Immersion fixation

• Secondary antibody: NorthernLights™ 557-conjugated Anti-Mouse IgG

• Counterstain: DAPI for nuclear visualization

For intracellular staining, additional permeabilization is required:

• Fix cells with paraformaldehyde

• Permeabilize with saponin

• Block with appropriate serum to reduce non-specific binding

The protocol should be optimized for each cell type, with special consideration for:

• Fixation duration (typically 10-15 minutes)

• Antibody concentration (titration recommended)

• Incubation temperature (4°C overnight vs. room temperature)

• Washing buffer composition and number of washes

• Mounting medium selection for signal preservation

Incorporating appropriate positive controls (GPR34-transfected cells) and negative controls (isotype antibodies) is essential for result interpretation .

What are the critical parameters for optimizing Western blot detection of GPR34?

For Western blot detection of GPR34, several critical parameters require optimization:

When analyzing GPR34 variants or mutations, researchers should be aware that C-terminal truncations may result in altered migration patterns on SDS-PAGE, necessitating careful interpretation of band sizes .

How can flow cytometry protocols be optimized for GPR34 detection in primary immune cells?

Optimizing flow cytometry for GPR34 detection in primary immune cells requires careful attention to several parameters:

• Surface vs. intracellular staining:

  • For surface detection: Use non-fixed or lightly fixed cells

  • For intracellular detection: Fix with paraformaldehyde and permeabilize with saponin

• Antibody selection and validation:

  • Use antibodies validated for flow cytometry (e.g., Mouse Anti-Human GPR34 MAB4617)

  • Include appropriate isotype controls (e.g., MAB003)

  • Validate antibody specificity using GPR34-negative populations

• Secondary antibody considerations:

  • For indirect detection: Phycoerythrin-conjugated Anti-Mouse IgG F(ab')₂

  • Consider directly conjugated antibodies to reduce background

• Panel design for immune cell analysis:

  • Include markers for specific immune subsets (e.g., macrophages, neutrophils, dendritic cells)

  • Consider the correlation between GPR34 and immune cell markers (e.g., strong correlation with macrophage markers)

• Gating strategy:

  • Establish hierarchical gating to identify specific populations

  • Use FMO (Fluorescence Minus One) controls for accurate positive/negative discrimination

• Sample preparation specifics:

  • Red blood cell lysis for peripheral blood samples

  • Gentle enzymatic digestion for tissue samples

  • Temperature control during processing to preserve receptor expression

This optimized approach enables accurate quantification of GPR34 expression across diverse immune cell populations, facilitating correlation with functional outcomes .

How can GPR34 antibodies be utilized to investigate its involvement in neuropathic pain mechanisms?

GPR34 has been implicated in neuropathic pain, with evidence suggesting its overexpression in microglia of the spinal dorsal horn following sensory nerve injury . To investigate this involvement, researchers can employ GPR34 antibodies in these advanced applications:

• Spinal cord immunohistochemistry:

  • Map temporal and spatial expression patterns of GPR34 following nerve injury

  • Co-localize with microglial markers (Iba1, CD11b) to confirm cellular specificity

  • Quantify expression levels correlated with behavioral pain measures

• In vivo target engagement studies:

  • Use GPR34 antibodies to validate target engagement of potential antagonists

  • Monitor changes in GPR34 expression and phosphorylation status with treatment

• Ex vivo functional studies:

  • Perform calcium imaging in microglia with GPR34 immunostaining

  • Correlate GPR34 expression with lysoPS-induced functional responses

• Translational research applications:

  • Compare expression patterns between animal models and human patient samples

  • Correlate GPR34 levels with pain severity measures and treatment responses

• Mechanistic investigations:

  • Combine with markers of microglial activation and inflammatory signaling

  • Investigate downstream pathways using phospho-specific antibodies

This multi-faceted approach can help elucidate the mechanistic role of GPR34 in neuropathic pain and validate it as a therapeutic target for pain management .

What methods can be employed to study the interaction between GPR34 and its endogenous ligand lysophosphatidylserine?

Investigating the interaction between GPR34 and its endogenous ligand lysophosphatidylserine (lysoPS) requires specialized techniques that can be enhanced with GPR34 antibodies:

• Migration assays:

  • Transfected cell lines (e.g., WEHI-231 mouse B lymphoma cells) with wild-type or mutant GPR34

  • Transwell migration assays with concentration-dependent lysoPS gradients

  • Quantification of migration responses and correlation with GPR34 expression levels

• Structural biology approaches:

  • Use antibodies to validate receptor conformations identified in cryo-EM studies

  • Epitope mapping to identify critical binding interfaces with lysoPS

  • Confirmation of structural changes upon ligand binding

• Binding studies:

  • Develop competition binding assays using labeled lysoPS

  • Assess binding kinetics in the presence of antibodies targeting different GPR34 domains

  • Correlate binding with functional outputs

• Signaling cascade analysis:

  • Monitor downstream signaling events following lysoPS stimulation

  • Assess the impact of GPR34 mutations on signal transduction pathways

  • Correlate signaling outputs with receptor expression levels

• In vivo validation:

  • Use genetic models with GPR34 knock-in or knockout

  • Assess lysoPS responses in primary cells isolated from these models

  • Correlate with in vitro findings

These approaches provide comprehensive insights into the molecular mechanisms of GPR34 activation by lysoPS and how this interaction influences cellular functions in physiological and pathological contexts.

How can researchers investigate the differential effects of GPR34 in various cancer models using antibody-based approaches?

GPR34 has been implicated in multiple cancer types, including glioma, gastric cancer, colorectal cancer, and cervical cancer . To investigate its differential effects across cancer models, researchers can employ these antibody-based approaches:

• Comparative expression profiling:

  • Quantify GPR34 expression across cancer tissue microarrays using standardized immunohistochemistry protocols

  • Correlate expression with clinical outcomes across cancer types

  • Use tissue-specific scoring systems calibrated with positive controls

• Functional impact assessment:

  • Compare knockdown/overexpression effects in multiple cancer cell lines:

    • Glioma: U251, LN229

    • Gastric cancer: appropriate cell lines

    • Colorectal cancer: appropriate cell lines

    • Cervical cancer: appropriate cell lines

  • Monitor common endpoints (proliferation, migration, invasion) with standardized assays

• Pathway analysis across cancer types:

  • Investigate cancer-specific mechanisms:

    • Glioma: EMT-like processes, cell cycle regulation, TGF-β/Smad signaling

    • Compare with dominant pathways in other cancer types

  • Use multiplexed immunofluorescence or phospho-flow cytometry with GPR34 antibodies

• Tumor microenvironment interactions:

  • Assess immune infiltration patterns associated with GPR34 expression

  • Compare immune correlation profiles across cancer types

  • Utilize single-cell approaches to delineate cell type-specific effects

• Therapeutic response prediction:

  • Correlate GPR34 expression with response to standard treatments across cancer types

  • Evaluate GPR34 as a biomarker for treatment selection

  • Assess potential for combination therapies targeting GPR34

This comparative approach can reveal both common mechanisms and cancer-specific roles of GPR34, informing tailored therapeutic strategies for different cancer types .

What are the most common challenges in GPR34 antibody experiments and how can they be addressed?

Researchers frequently encounter several challenges when working with GPR34 antibodies that require specific troubleshooting approaches:

For optimal GPR34 detection, researchers should validate antibodies using appropriate positive controls, such as GPR34-transfected HEK293 cells, and negative controls like mock-transfected cells . This validation is particularly important given the membrane protein nature of GPR34 and its various isoforms.

How can researchers validate GPR34 antibody specificity in their particular experimental system?

Validating GPR34 antibody specificity is critical for generating reliable research data. Researchers should implement these validation strategies:

• Genetic validation approaches:

  • Compare staining in wild-type versus GPR34 knockout models

  • Use siRNA/shRNA knockdown systems to create negative controls

  • Employ overexpression systems as positive controls

• Epitope competition assays:

  • Pre-incubate antibody with excess immunizing peptide

  • Compare staining with and without competition

  • Observe elimination of specific signal with peptide competition

• Multi-antibody validation:

  • Use antibodies targeting different epitopes

  • Compare staining patterns across antibodies

  • Consistent patterns suggest specific detection

• Recombinant protein controls:

  • Test antibodies against purified recombinant GPR34

  • Include related G-protein coupled receptors to assess cross-reactivity

  • Quantify affinity and specificity parameters

• Cell line validation matrix:

  • Test across multiple cell lines with known GPR34 expression profiles

  • Include GPR34-transfected HEK293 cells as positive controls

  • Include native HEK293 (MOCK) cells as negative controls

• Method-specific validation:

  • For Western blot: Confirm expected molecular weight (~40-50 kDa)

  • For ICC/IHC: Verify cellular/subcellular localization patterns

  • For flow cytometry: Compare with isotype controls (e.g., MAB003)

Proper validation increases confidence in experimental findings and facilitates comparison across studies using different antibodies or detection methods.

How might structural insights from cryo-EM studies influence the development of new GPR34 antibodies and research applications?

Recent cryo-EM studies of GPR34 in both activated and inactivated states provide unprecedented structural insights that will significantly impact antibody development and research applications :

• Epitope-specific antibody development:

  • Design antibodies targeting conformation-specific epitopes

  • Generate antibodies that distinguish between activated and inactivated states

  • Develop antibodies targeting unique structural domains identified by cryo-EM

• Structure-based functional studies:

  • Use conformation-specific antibodies to map receptor activation states in situ

  • Correlate structural conformations with downstream signaling events

  • Investigate the dynamics of receptor activation in living cells

• Antagonist development and validation:

  • Use structural data to guide development of GPR34 antagonists

  • Employ antibodies to confirm target engagement

  • Correlate antagonist binding with structural changes and functional outcomes

• Domain-specific functional mapping:

  • Develop antibodies targeting specific functional domains

  • Investigate domain-specific roles in ligand recognition, G-protein coupling, and receptor trafficking

  • Correlate domain functions with pathological processes

• Therapeutic antibody development:

  • Design therapeutic antibodies that modulate GPR34 function

  • Target disease-specific conformations or epitopes

  • Leverage structural data for optimization of binding and specificity

These approaches will expand the research toolkit available for GPR34 studies while potentially yielding new therapeutic modalities for GPR34-associated diseases .

What are the current challenges and opportunities in developing therapeutic approaches targeting GPR34?

The development of therapeutic approaches targeting GPR34 presents both challenges and opportunities based on current research :

Challenges:

• Target validation across diseases:

  • While GPR34 shows promise in conditions like neuropathic pain and glioma , more validation is needed for other disease contexts

  • Requirement for disease-specific biomarkers of GPR34 activity

• Selectivity issues:

  • Distinguishing GPR34 from related lysoPS receptors

  • Avoiding off-target effects on other GPCRs

  • Tissue-specific targeting to minimize systemic effects

• Complex signaling mechanisms:

  • Multiple downstream pathways (TGF-β/Smad signaling in glioma)

  • Context-dependent signaling outputs

  • Compensatory mechanisms following GPR34 inhibition

Opportunities:

• Structural insights enabling rational drug design:

  • Cryo-EM structures in both active and inactive states

  • Structure-based antagonist development

  • Allosteric modulator design targeting specific conformations

• Promising preclinical findings:

  • GPR34 knockout models show reduced neuropathic pain

  • GPR34 inhibition reduces malignant phenotypes in glioma models

  • GPR34 knockout mice show no obvious abnormalities, suggesting favorable safety profile

• Novel therapeutic modalities:

  • Small molecule antagonists

  • Function-modulating antibodies

  • Targeted degradation approaches

  • Gene therapy for chronic conditions

• Clinical translation strategies:

  • Biomarker-guided patient selection

  • Combination therapies targeting GPR34-associated pathways

  • Disease-specific formulations and delivery approaches